ArticleJournal of clinical medicine2022

Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors.

Chien-Chang Kao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.